In a move that sees another senior GlaxoSmithKline executive leave thecompany following its recent merger (last week it was revealed that George Morrow was joining Amgen; Marketletter January 15), Roche has named George Abercrombie as president and chief executive of its North American pharmaceuticals operations, which include Hoffmann-La Roche Inc in Nutley, New Jersey, and the Canadian affiliate Hoffmann-La Roche Ltd in Mississauga, Ontario.
Mr Abercrombie, who was senior vice president of US commercial operations at Glaxo Wellcome, succeeds Patrick Zenner, who announced his retirement last October after 31 years with the company, the last eight as president and CEO. Mr Abercrombie will report to William Burns, the recently-appointed head of Roche's global Pharmaceuticals Division.
In his previous position in charge of US commercial operations at Glaxo Wellcome, Mr Abercrombie's responsibilities encompassed pharmaceutical sales and marketing, managed care, state government affairs, e-commerce, disease management, business planning and development, and late-stage clinical drug studies. He first joined the company as vice president and general manager of the Glaxo Pharmaceuticals Division in 1993, following 10 years at Merck & Co, where he held a broad range of positions in sales, marketing, executive sales management and business development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze